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ABSTRACT
Antitumor and radiosensitizing effects of (E)-2'-deoxy-2'-(fluorometh-
ylene) cytidine (FMdC), a novel inhibitor of ribonucleotide reducÃ-ase,
were evaluated on nude mice bearing s.c. human C33-A cervix cancer and
I -H7 MG glioblastoma xenografts. FMdC given once daily has a dose-
dependent antitumor effect. The maximum tolerated dose in the mice was
reached with 10 daily i.p. administrations of 10 mg/kg over 12 days. In the
case of radiotherapy (RT) alone (10 fractions over 12 days), the radiation
dose required to produce local tumor control in 50% of the treated C33-A
xenografts was 51.0 Gy. When combined with FMdC, the radiation dose
required to produce local tumor control was reduced to 41.4 and 38.2 Gy,
at respective doses of 5 and 10 mg/kg given i.p. l h before each irradiation.
The corresponding enhancement ratios (ERs) were 1.2 and 1.3, respec
tively. In U-87 MG xenografts, when 5-20 mg/kg FMdC combined with 30
or 40 Gy of RT, the combination treatment produced a significantly
increased growth delay as compared with RT alone (P Â£0.002). The ERs
of 5, 10, and 20 mg/kg FMdC at a dose of 30 Gy were 2.0, 1.4, and 1.8,
respectively. At the 40-Gy level, ERs of 10 and 20 mg/kg FMdC were 1.4
and 1.7. When FMdC was combined with 50 Gy of RT, an increased
long-term remission rate of 80-88.9% was observed, as compared with
25% for RT alone (P <0.05). FMdC produced moderate myelosuppres-
sion in the mice bearing cervix cancer, whereas leukocytosis occurred in
the mice bearing glioblastoma at a low dose. Slightly increased skin
toxicity (only with U-87 MG tumor) was observed, as compared with RT
alone. In conclusion, FMdC is a potent cytotoxic agent and able to modify
the radiation response of C33-A and U-87 MG xenografts.
INTRODUCTION
FMdC5 (1, 2), a novel compound synthesized to exert irreversible
and potent inhibition of RR, is a very effective cytotoxic agent against
a variety of common human cancers (3-7). Moreover, it has been
shown to act as a radiosensitizer both in vitro (8) and in vivo (7).
The antitumor effect and radiosensitization can be explained by the
effect on RR and subsequent alteration of the dNTPs. It has been
shown by others that RR, an enzyme that catalyzes a rate-limiting step
in DNA synthesis, has an increased activity in rapidly growing tumors
(9) and that alteration of the dNTP pool is related to the modification
of radiation response (10). Takahashi et cil. (6) showed recently that
FMdC induced long-lasting inhibition of RR and resulted in a deple
tion of the dCTP. dATP, and dGTP pools and an increase in the TTP
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pool. Other drugs such as hydroxyurea or gemcitabine, acting on the
same target, also have been shown to be potent radiosensitizers
(11-13). Recently, We have observed that the radiosensitizing effect
of FMdC is evident in a human colon cancer WiDr xenograft model
(7); however, whether FMdC also has a similar radiosensitizing effect
on other types of human cancers in vivo is not clear. In this study, we
decided to further evaluate the capacity of FMdC to act as a radiation
sensitizer in a human cervix cancer C33-A with a mutated p53 (14)
and a glioblastoma U-87 MG with a wild type of p53 (15) xenografted
in nude mice.
MATERIALS AND METHODS
Chemicals and Cell Lines. FMdCIMDL 101,731) was kindly provided by
Marion Hoechst Roussel, Inc. (Cincinnati. OH). Cell culture media and sup
plements were purchased from Lite Technologies. Inc. (Basel, Swit/erland).
PCS was obtained from Fakola.
The human C33-A cervix cancer cell lines were obtained from the American
Type Culture Collection (Manassas, VA). The human glioblastoma U-87 MG
cell line was a gift from the Department of Neurosurgery at our hospital. Cells
were grown as a monolayer in Eagle's MEM with WJr FCS. 2 mM L-
glutamine. and \'7< penicillin-streptomycin. To establish tumors in nude mice.
cells in exponential growth phase were harvested after a 3-min incubation with
Trypsin (0.05%)-EDTA (0.02%) solution and resuspended in serum-free
MEM. A suspension of about 5 x I0ft cells was inoculated s.c. in the dorsum
of the Swiss nude mice. For the experiments, animals were implanted with
tumors at least three passages away from the initial source.
s.c. Tumor Model. All experiments in nude mice were performed accord
ing to Swiss legislation and approved by the official committee of surveillance
of animal experiments. Female Swiss homozygous nu/nu nude mice, 7-9
weeks of age. were given a s.c. transplantation in the midline of the back at 2
cm from the tail of a volume of about 30 mm' of freshly excised, minced tumor
tissues. Three to 4 weeks after inoculation, the mice bearing tumors of
approximately 80-160 mm' volume, with a mean tumor volume ot about 120
mm1, were assigned randomly tor the control or the test treatment groups.
Irradiation of Tumors. X-rays were generated by a Philips RT 250
operating at 200 kV and 20 mA. The beam was filtered with 0.5 mm Cu
(halt-value layer = 1 mm Cu). Up to six mice/irradiation were restrained in
3-mm lead jigs designed with a cutout 20- X 14-mm to expose their lower
dorsum. The jigs were placed in a perspex box with an additional lead shield
with 60- X 17-mm openings; in each field, two mice were exposed tail-on-tail.
This setup gives minimal scatter to the animals placed at 52.5 cm from the
source. The X-ray beam hits the tumors tangentially to the dorsum. The dose
rate in this setup was 0.64 Gy/min with a dose heterogeneity of Â±5.5% for an
8-mm tumor. To obtain dose homogeneity, the mice were rotated through 180
degrees at alternate treatments. The treatment regime consisted of 10 fractions
over 12 days (5 fractions/week comparable with a clinical fractionation sched
ule).
Antitumor Effects of FMdC. Nude mice with s.c. tumor xenografts were
treated Â¡.p.with 1. 5. 10, and 20 mg/kg FMdC. once daily. 5 days/week for up
to 2 weeks.
Radiosensitizing Effect of FMdC. FMdC dissolved in saline and sterili/ed
by filtration through Millipore 0.22 pim was administrated i.p. l h before each
irradiation for 2 weeks with a 2-day rest during the weekend. All RT or
RT-FMdC combined groups were evaluated in two blocks, each block includ
ing half of the mice of each group with similar-si/ed tumors. Each group
consisted of 8-13 mice.
Experimental End Points. After treatment, three perpendicular diameters
of each tumor were measured with calipers twice a week. Complete or partial
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Fig. I. The effects of FMdC given as once daily i.p. administrations (10 times over 12
days) on (he growth of C33 carcinoma xenografts in nude mice. The mean tumor volume
relative to the initial tumor volume at day 0 is plotted versus time for each group (Â±SE).
The tumor volumes at day 0 were 82.7 Â±38.1, 81.1 Â±32.9. 102.7 Â±19.7. 118.5 Â±37.5,
and 128.8 Â±39.9 mm' for groups of control. 1. 5. 10. and 20 mg/kg FMdC, respectively.
regressions were assessed once/week. The tumor volume was calculated using
the formula: V = length X width X thickness/2. The relative tumor volume
(V/Vo) was calculated by dividing the measured tumor volume (V) by the
initial tumor volume (vo) at day 0.
Tumor responses were quantified by tumor regrowth delay, local control,
and long-term remission. Tumor regrowth delay was expressed as AGD and
NGD. AGD was defined as the time for tumor volume in the treated groups to
increase by five times the initial treatment size minus the time in the untreated
control group to reach the same size. NGD was defined as the time for tumor
volume to increase by five times the initial treatment size in the mice treated
by the combination of FMdC and radiation minus the time for tumors to reach
the same size in the mice treated with FMdC alone. Local control for the
C33-A tumor is defined as absence of palpable tumor mass at 120 days after
the end of the treatment. All regrowing tumors were recorded as relapse in the
analysis whether or not the tumor diameter was smaller than that of the first
day of irradiation. The percentage of controlled tumors at 120 days was plotted
for each group, and the data were fitted by logit analysis. The effect of graded
doses of radiation given alone or in combined regimens was evaluated as the
TCDM1. The ER for C33-A tumor was calculated as the ratio of TCD50
produced by radiation alone to TCDSO produced by combined FMdC and
radiation. Because U-87 MG glioblastoma lacks an apoptotic cell death path
way (16) and is a very radioresistant tumor that has a TCD50 of 75.2 Gy under
clamp hypoxia using single-dose irradiation (17), the local control rate was not
available. Therefore, we used long-term remission for the U-87 MG tumor,
which was defined as absence of palpable or residual tumor mass <2 times of
initial volume 180 days after the end of treatment. To calculate the ER, we also
included these long-term remission tumors and arbitrarily took 180 days as the
time for these tumors to grow to five times the initial treatment size. The ER
for the U-87 MG glioblastoma was calculated as the ratio of the NGD
produced by combined FMdC and radiation to the AGD produced by radiation
alone.
Toxicity Evaluation. Local skin toxicity of RT was evaluated by inspec
tion three times/week for the first 5 weeks, and then twice/week. The skin
toxicity in the radiation field was scored as follows: I. local erythema: II. moist
desquamation; and III. complete ulcÃ©ration.Toxicity after injections of FMdC
alone or combined with RT was evaluated by body weight measurements and
peripheral WBC counting. Body weight was measured three times weekly
from the first injection of FMdC until 4 weeks after the end of the treatment,
and the weight loss was expressed as a percentage of the initial weight
(<initial weight - lowest weight>/initial weight x 100%). Peripheral WBCs
were monitored 1 day after the end of FMdC treatment and 3 days after
finishing radiation treatment alone or combined with FMdC (correlated with
the nadir of WBC at those moments). WBCs were counted in 15 p.\ of blood
(obtained from the tail vein) diluted 1:10 in Turck solution and manually
counted. Lower limb paralysis was recorded after treatment.
Histopathological Studies. The s.c. tumors that were untreated or treated
with 10 daily administrations of 10 mg/kg FMdC (once daily, 5 days/week)
were removed from nude mice 24 h after the last treatment and fixed in 4%
buffered formalin. The residual tumor masses (which were defined as long-
term remission) were also fixed in 4% buffered formalin, 6 months after the
end of treatment. The specimens were embedded in paraffin, and 4-/im thick
sections were stained sequentially with H&E for microscopic examination.
Potential Doubling Time and Volume Doubling Time. The potential
doubling times of C33-A and U-87 MG tumors were measured by iodode-
oxyuridine labeling and flow cytometry. The mice bearing C33-A or U-87 MG
tumors were given i.p. injections of iododeoxyuridine 6 h before the tumors
were removed. The dose administrated was 150 mg/kg. The s.c. tumors were
fixed in 70% ethanol and stored at 4Â°Cin the dark until analysis. Preparation
of samples for flow cytometry was according to the method of Begg (18).
Briefly, the tumor samples were cut into small pieces in Petri dishes and
digested with 0.4 mg/ml pepsin for l h at 37Â°C,which produced a suspension
of nuclei. DNA of the nuclei was denatured with 2N HC1 for 20 min at 37Â°C.
Antibody staining consisted of the mouse anti-iododeoxyuridine antibody
(1:100 dilution; ParteÂ« AG, Basel, Switzerland) followed by an FlTC-conju-
gated goat antimouse IgG antibody (1:50 dilution; Parted AC). Total DNA
was stained with 50 /ig/ml propidium iodide. Flow cytometric analysis was
carried out using FACScan flow cytometry (Becton Dickinson). The methods
for calculating potential doubling time has been described previously (19). The
volume doubling times were individually estimated from the growth curves of
the tumors xenografted in the mice.
Statistical Analysis. Tumor AGD, NGD, and hematological toxicity in the
various conditions of therapy have been compared using the Student's / test
(two-tailed). For comparison of long-term remission rates, the )C test was used.
TCD50 was calculated according to the logit analysis.
RESULTS
Antitumor Effects of FMdC on C33-A and U-87 MG Tumor
Xenografts. The response of C33-A xenografts to FMdC was dose-
dependent (Fig. 1). Even at the low dose (i.e., 1 mg/kg), we observed
a significant antitumor effect as compared with untreated control (P
<0.0001). Significant higher tumor shrinkage was observed at 20
mg/kg FMdC. No significant body weight loss (S4.0%) was observed
at the dose <5 mg/kg, whereas a 7.0% and 13.0% weight loss were
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Fig. 2. Peripheral blood leukocyte analysis of mice bearing C33-A and U-87 MG
lumors 1 day after the end of FMdC treatment ( Â±SE). The leukocyte counts of normal
mice without lumors were 10,900 Â±680/mm' (n = 12; mean Â±SE).
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Fig. 3. The effects of FMdC given as once daily i.p. administrations ( 10 times over 12
days) on growth of U87 MG xenografts in nude mice (Â±SE). In the 20-mg/kg group. I
of 11 mice died of acute toxicity (data not included).
<0.05). Even at a dose as high as 20 mg/kg, we did not observe toxic
death. As far as hematological toxicity was concerned, we did observe
a significant reduction of leukocyte counts from doses >5 mg/kg as
compared with untreated controls (P <0.001), but no further decrease
at higher doses (Fig. 2). Petechiae did not appear.
For U-87 MG xenografts, the antitumor effect became significant at
doses >5 mg/kg (Fig. 3). However, no further increase in AGO was
observed at a higher dose (i.e., 20 mg/kg), as compared with 10 mg/kg
(P = 0.18). There was also a moderate weight loss (9.5%) at a dose
of 20 mg/kg (P <0.05). In contrast to the mice bearing C33-A
xenografts, we had to face toxic death in 1 of 11 mice (9.1%) treated
at the higher dose level of 20 mg/kg. Tumor shrinkage did not appear,
even up to a dose of 20 mg/kg, but significant prolonged AGDs were
observed at doses of 5-20 mg/kg as compared with the untreated
control (P <0.0001). In contrast to the C33-A model, a rise of
leukocyte counts was observed at lower doses of 1 and 5 mg/kg in the
U-87 MG model (P <0.0001). However, at the higher dose level, the
leukocyte counts were significantly decreased compared with un
treated control mice (P <0.0001; Fig. 2).
Mice surviving a higher dose of FMdC (i.e., 20 mg/kg) recovered
their body weight within 7-10 days and their leukocyte counts com
pletely within 10-14 days after the end of treatment (data not shown).
Radiosensitizing Effect of FMdC. The responses of C33-A tu
mors to radiotherapy were dose-dependent, and the TCD50 for RT
alone was 51.0 Â±1.1 Gy (Â±95% confidence limits; Fig. 4). When 5
mg/kg FMdC was given i.p. l h before each irradiation, the dose effect
curve was shifted to the left and the TCD5() dropped to 41.4 Â±1.1 Gy
(Fig. 4). When 10 mg/kg FMdC was used, the TCD50 was reduced to
38.2 Â±1.1 Gy (Fig. 4). The ERs at the TCD50 level were 1.2 and 1.3
for 5 mg/kg and 10 mg/kg FMdC, respectively. The irradiated mice
showed neither significant weight loss (data not shown) nor enhanced
hematological toxicity (Fig. 5A), as compared with FMdC treatment
alone. There was no increased skin toxicity with combined FMdC and
RT as compared with RT alone (data not shown).
The response of U-87 MG tumors to RT were also dose-dependent
(Fig. 6). When 5, 10, or 20 mg/kg FMdC were combined with 30 Gy
of RT (Fig. 7), the tumor AGDs were significantly increased as
compared with RT alone (P <0.002, P <0.0007, and P 5=0.0001 for
5, 10, and 20 mg/kg FMdC, respectively). If the AGDs produced by
combined FMdC and RT were corrected for AGDs produced by
FMdC alone, the corresponding ERs at the doses of 5, 10, and 20
mg/kg FMdC were 2.0, 1.4, and 1.8, respectively (Table 1). The
results were confirmed in a second experiment, in which a RT of 40
Gy was combined with 10 or 20 mg/kg FMdC (Fig. 8). Again, the
AGDs produced by combined RT and FMdC were significantly
prolonged as compared with RT alone (P <0.002). The corresponding
ERs at the doses of 10 and 20 mg/kg FMdC were 1.4 and 1.7,
respectively (Table 1). However, as mentioned earlier, the toxic death
was observed at the dose of 20 mg/kg. The long-term remission rate
was also increased from 20% in cases of RT alone to 50% in cases of
RT combined with 20 mg/kg FMdC (Fig. 8), but this difference was
not significant (P >0.05). When FMdC was combined to 50 Gy of
RT, a significantly increased long-term remission rate was observed
as compared with RT alone (P <0.05; Table 2). However, the long-
term remission rate was similar at the dose of 5 mg/kg as compared
with 20 mg/kg.
Side effects of combined RT and FMdC in the mice bearing U-87
MG tumors were not the same as in the mice bearing C33-A tumors.
At the dose of 5 mg/kg, the irradiated mice showed decreased leuko
cyte counts as compared with FMdC treatment alone (P <0.05);
however, the leukocyte counts were still higher than or similar to that
of untreated control, even at a dose of 50 Gy (Fig. 5ÃŸ).At the doses
of 10 mg or 20 mg/kg, the irradiated mice showed no enhanced
hematological toxicity as compared with FMdC alone (Fig. 5fi).
Increased toxicity, however, was observed at a higher radiation dose
level (50 Gy) when 10 mg/kg FMdC was combined with RT (P
<0.001). No significant weight loss was observed in all groups as
compared with FMdC alone (data not shown). When 20 mg/kg FMdC
was combined with RT, 9-18% of the treated mice died of toxicity
10-14 days after treatment (see Table 2 and legends to Figs. 7 and 8).
The hematological toxicity might not be the main reason of death,
because bone marrow transplantation with blood tranfusion did not
reduce the death rate (7). When FMdC was combined with RT, skin
toxicity was slightly increased as compared with RT alone, especially
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Fig. 4. Local tumor control of C33 xenografts to RT combined to daily 5 or 10 mg/kg
FMdC. RT was given in 10 fractions over 12 days, and FMdC was given i.p. l h hefore



















Dose of Radiotherapy (Gy)
Fig. 5. Peripheral blood leukocyte analysis of mice bearing C33-A (A) and U-87 MO (fi) xenografts 3 days after the end of treatment with combined FMdC and RT (Â±SE).
30 40 50
Dose of Radiotherapy (Gy)
at the 40-Gy level (see Fig. 8 legend). Local acute skin reactions
appeared about 12 days after treatment initiation, and the healing of
radiation-damaged skin generally occurred 2-3 weeks after the end of
treatment. One of 10 mice died of lower limb paralysis 3 months after
the end of treatment in the group of 20 mg/kg FMdC + RT of 50 Gy.
Histopathological Studies. No significant necrotic areas were ob
served in the untreated s.c U-87 MG tumors (Fig. 9A), unless in the
center of some tumor nodules (data not shown). Swollen and/or
necrotic tumor cells, as well as infiltrated inflammatory cells, were
observed after 10 daily i.p. treatments of 10 mg/kg FMdC (Fig. 9ÃŸ).
Mitotic figures were evident in untreated control tumors, but not in the
tumors treated with FMdC (data not shown). Significant interstitial
fibrosis and concurrent inflammatory cell infiltration were observed in
the residual U-87 MG tumor mass 6 months after the end of treatment
with combined RT (40 Gy) and FMdC (20 mg/kg; Fig. 9C, top).
Enlarged or swollen tumor cells with enlarged irregular nuclei con
taining chromatin clumps were observed in some residual tumor
masses (Fig. 9C, top). In those samples containing no residual tumor
cells, only fibrosis without inflammatory cells was observed (Fig. 9C,
bottom). This may indicate that inflammatory cells are involved in the
process of removing dead tumor cells, because apoptotic cell death is
not apparent in U-87 MG glioblastoma (16).
Swollen and/or necrotic tumor cells were observed in C33-A tu
mors treated with 10 daily i.p. treatments of 10 mg/kg FMdC, how
ever, no infiltrated inflammatory cells were visible (Fig. 9, E and F).
Apoptotic cells were visible after FMdC treatment (Fig. 9F).
Potential Doubling Time and Volume Doubling Time. Under
our experimental conditions, the potential doubling times of untreated
C33-A and U-87 MG tumors were 2.1 Â±0.6 (n = 4) and 1.6 Â±0.4
(n = 4) days, and the volume doubling times were 3.4 Â±0.9 (n = 15)
and 3.3 Â±0.7 (n = 10) days, respectively.
DISCUSSION
The results of these in vivo studies provide experimental evidence
that FMdC may be an effective anticancer agent in the treatment of
human cervix cancer and glioblastoma. This compound induces re
gression of s.c. tumors in a dose-dependent manner. Progressive
tumor regrowth after the end of FMdC treatment alone, indicates that
the daily administrations of FMdC are not curative for s.c. tumors. As
far as toxicity is concerned, we demonstrated that 10 daily adminis
trations of 10 mg/kg FMdC over 12 days was the maximum tolerated
dose in the mice. Daily doses >10 mg/kg for 10 times failed to
produce more antitumor effects in the U-87 tumor, but resulted in a
moderate weight loss and increased toxic death. As compared with
untreated controls, the leukocyte counts in the mice bearing C33-A
tumor were significantly reduced after treatment with a dose >5
mg/kg, whereas the leukocyte counts were significantly increased
after treatment with 1-5 mg/kg FMdC in the mice bearing U-87
glioblastoma. However, at a higher dose (i.e., 20 mg/kg), the reduced
leukocyte counts were also observed in the U-87 MG model. The
reduced leukocyte counts in the mice bearing C33-A tumors could be
explained by direct cytotoxicity of FMdC to bone marrow. However,
the exact mechanism by which leukocytosis occurs in the mice bear
ing U-87 MG tumor treated with a low dose of FMdC is not clear (20,
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Fig. 6. The effects of RT at different total doses on the growth of U-87 MG xenografts.
RT was given in 10 fractions over I2 days (Â±SE).
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Fig. 7. The effects of 30 Gy of RT alone or combined with FMdC on the growth of
U-87 MG xenografts ( Â±SE). In the group of 30 Gy + 20 mg/kg FMdC, 2 of 11 mice died
of acute toxicity 1-2 weeks after treatment (data not included).
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" Geometric mean Â±SD.
FMdC was given as once daily i.p. injections, 10 times over 12 days.
' AGO.
RT was given in 10 fractions over 12 days.
'' NGD.
human malignant breast, colon, prostate, and brain tumors. In these
tumors, a dramatic tumor regression of s.c.-implanted tumors was
obtained and a significant prolongation of survival was observed in
intracerebral implants and liver mÃ©tastases,as well as a reduction of
the number of lung mÃ©tastases(3-5, 7).
More importantly, FMdC significantly increased radiation response
of human cervix cancer and gliobla.stoma xenografts. The ERs for
C33-A tumor at TCD50 levels were 1.2 and 1.3 for 5 and 10 mg/kg
FMdC applied daily, respectively. However, the ERs for C33-A tumor
are less important as compared with WiDr tumors in which ERs of 1.9
and 2.4 were observed (7). One of the reasons for the differences may
be that C33-A is a more aggressive tumor than the WiDr tumor. The
potential doubling time and volume doubling time were 2.1 and 3.4
days for the C33-A tumor and 3.0 and 6.4 days for the WiDr tumor,
respectively. Significantly increased AGDs and long-term remission
rates were observed in U-87 MG tumors when 5-20 mg/kg FMdC
were combined with RT. Combining FMdC (5-20 mg/kg) with RT
(30 or 40 Gy ) produces a better therapeutic effect, with an ER ranging
from 1.4-2.0. When 5-20 mg/kg FMdC were combined with 50 Gy
of RT, significantly increased long-term remission rates of the treated
tumors (80-88.9%) were observed, as compared with RT alone
(25%). However, the high dose of FMdC (i.e., 20 mg/kg) is not able
to further increase a long-term remission rate as compared with 5
mg/kg.
The addition of FMdC to irradiation did not increase skin toxicity,
weight loss, or hematological toxicity in the mice bearing C33-A
tumors. A moderate increase of hcmatological toxicity was observed
in the mice bearing U-87 MG tumors, when a higher dose of RT (50
Gy) was combined with 10 mg/kg FMdC. However, the hcmatolog
ical toxicity was well-tolerated and was reversible. We do not know
why the slightly increased skin toxicity was observed in the mice
bearing U-87 MG tumors and not in the mice bearing C33-A and
WiDr tumors (7).
Because of direct measurements of RR. dNTP pools and DNA
repair were not performed in our studies, the precise mechanism of
FMdC can only be inferred from prior studies. FMdC is a potent
member of a class of mechanism-based inhibitors of RR, the enzyme
responsible for de novo production of dNTPs by reduction of ribonu-
cleotide at the level of diphosphates. The drug acts in a manner similar
to other RR inhibitors such as hydroxyurea and gemcitabinc, which
has been shown to cause inhibition of DNA synthesis specifically,
without significantly inhibiting either protein or RNA synthesis. In
hibition of DNA synthesis with these drugs is most probably due to a
decrease in one or more of dNTP pools (6, 22-25) or chain termina


















20 40 60 80 100120140 200
Time After Treatment (Days)
Fig. 8. The effects of 40 Gy of RT alone or combined with FMdC on the growth of
U-87 MG xenografts ( Â±SE). In the group of 40 Gy + 20 mg/kg FMdC. I of 11 mice died
of acute toxicity 2 weeks after treatment (data not included). In the group of RT alone, i
of 10 mice had skin toxicily grade 1. In the group of RT + 10 mg/kg FMdC. I of 10 mice
had skin toxicity grade II. and 4 mice had grade 1. In the group of RT + 20 mg/kg FMdC.
I of 10 survived mice had skin toxicity grade III. 3 mice had grade II, and 6 mice had
grade I.















" RT was given in 10 fractions over 12 days, and FMdC was given I h before each
irradiation.
* P <0.05 as compared with RT alone.
' No. of (long-term) remission from 9 of 10 mice that survived.
J P <0.001 as compared with RT alone.
' One mouse died of lower limb paralysis 3 months after treatment.
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Fig. 9. Histology of human gHobIasiÃ³ma U-87 MG (A-D and human cervix cancer C33-A (D-/7)- The s.c. tumors treated with 10 daily administrations of 10 mg/kg FMdC were
removed for analysis 24 h after the last treatment (/?, Â£.and /â€¢*).The residual tumor masses were removed for analysis 6 months after the last treatment of combined FMdC of 20 mg/kg
with RT of 40 Gy (CI. C2), In untreated tumors (A and D), tumor cell morphology is well preserved. In FMdC-trealed tumors, swollen and/or neerotic tumor cells are observed (B
and Â£").CI. residual abnormal tumor cells with a significant amount of interstitial fibrosis are observed. C2, only fibrosis (without residual tumor cells) is observed. B and CI. infiltrating
inflammatory cells are detectable. F, apoptotic cells are visible (arrow head). Images of A-E were captured through a x 10 objective; F was captured through a X40 objective.
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abine (26). Although not proven in the present study, it is likely that
FMdC exerts its radiosensitizing effects through inhibition of irradi
ation-induced DNA repair processes. The reduced availability of
DNA precursors or perturbation of dNTP pools (6) may result in an
impairment of radiation-induced DNA damage repair and may be an
important determinant of radiosensitization with FMdC (8). This has
been shown in other RR inhibitors such as hydroxyurea (13) and
gemcitabine (11, 12). Other drugs active on the dNTP pools have been
shown to be potent radiosensitizers, such as fluorodeoxyuridine (in
hibition of thymidylate synthase and depletion of dTTP pools; Refs.
27-31 ) and the thymidine analogues, bromodeoxyuridine and iodode-
oxyuridine (depletion of dCTP and TTP pools; Refs. 10 and 32). Thus,
the antitumor and radiosensitizing effects of FMdC may be associated
with the depletion and intracellular imbalances of dNTP pools. The
reduced availability of DNA precursors or perturbation of dNTP pools
may also induce apoptotic or programmed cell death (33) and induce
p53-mutated cells to progress into S phase (27, 30, 31, 34, 35).
Lawrence hypothesizes that S phase progression seems to be a key
factor in the cytotoxicity and radiosensitization of a variety of S
phase-active agents, because if tumor cells were treated with aphidi-
colin, S phase progress is arrested and the cytotoxicity and radiosen
sitization does not occur (10, 30, 31). Regardless of the precise
mechanism, the above studies show compelling evidence that FMdC
may be an effective antitumor and radiosensitizing agent for treatment
of human cervix cancer and glioblastoma and probably also for other
tumors.
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